GBX beats fiscal Q3 earnings estimates, but its shares slide after the results as the company narrows its 2026 EPS guidance ...
Every evolution in software development has reduced the friction between an idea and a deployable application. AI may remove ...
United Therapeutics is a Buy: strong core growth, a goal of $1B quarterly revenue by 2027, plus catalysts ralinepag & Tyvaso ...
Sell-offs create opportunities, especially for these three stocks ...
KeyCorp's favorable updates regarding loan growth and deposit management support the case for a potential 2Q2026 earnings ...
Each of these stocks represents companies playing a critical role in the AI ecosystem.
TD Cowen maintained its 'Buy' rating on TransMedics with a $120 price target, which represents a potential upside of about 77 ...
Asthma is the most common chronic airway disease worldwide, imposing substantial clinical, societal, and economic burden.
Strategic collaboration at Sanford, North Carolina facility, currently under construction, to optimize cGMP validation, accelerate time-to-market for complex biologics, and shore up U.S. medicine ...
By lowering the fiscal barrier to high-frequency image generation, Google is making a direct play to lock enterprise ...
Vietnam Investment Review on MSN
Brii Bio phase 2b hepatitis B data from ENRICH and ENHANCE studies released
DURHAM, N.C. and BEIJING, July 3, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...
Assistant professor of practice, psychology and human development, and VKC member Jessika Boles, Ph.D., and colleagues have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results